News MapLight shares track up after $251m IPO MapLight Therapeutics has made its debut on the Nasdaq, raising $251m for a lead drug that could be a rival to BMS' new schizophrenia drug Cobenfy.
News BMS builds in 'in vivo' cell therapy with $1.5bn Orbital buy Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics, a developer of in vivo cell therapies, for $1.5bn in cash.
News Three more pharmas join OpenFold3 AI consortium Bristol Myers Squibb, Takeda, and Astex have joined a consortium working on refining the OpenFold structure prediction platform with industry data.
News BMS adds discounted psoriasis drug to its DTC channel Bristol Myers Squibb expands its DTC sales in the US with the addition of psoriasis drug Sotyktu at an 80% discount for cash buyers.
News BMS eyes filings for myeloma 'celmod' iberdomide Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after a positive phase 3 trial.
News BMS says it will set Cobenfy's UK price the same as the US Bristol Myers Squibb's price tag for schizophrenia drug Cobenfy in the UK is a manifestation of Trump's most favoured nation drug pricing policy.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.